Form 4: Bicycle Therapeutics Officer Sells Shares for Tax

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, sold 723 ordinary shares in non-discretionary transactions to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics PLC, sold a total of 723 ordinary shares.
• The sales occurred on October 2, 2025 (473 shares) and October 3, 2025 (250 shares).
• The weighted average sale prices were $8.40 per share (ranging from $8.37 to $8.45) and $8.41 per share (ranging from $8.40 to $8.50), respectively.
• These transactions were non-discretionary "sell to cover" sales, mandated by the reporting person's award agreement to satisfy statutory tax withholding obligations upon the vesting and settlement of restricted stock units.
• Following these transactions, Michael Charles Ferguson Hannay beneficially owns 53,102 ordinary shares directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting, which is a neutral event for the company's operational or financial performance. It does not indicate a lack of confidence by the insider.

Positives

• The underlying event is the vesting and settlement of restricted stock units, which represents earned compensation for the employee.

Negatives

• No discretionary sales by the officer, indicating the sales were for a specific, non-discretionary purpose (tax withholding) rather than a reflection of negative sentiment.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which reports past insider transactions.

Industry Context

This filing reports a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape.

Comparison to Industry Standards

• Not applicable, as this filing details a standard insider 'sell to cover' transaction for tax obligations, which is a common practice across industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not a reflection of insider sentiment. The number of shares sold is relatively small compared to the company's total outstanding shares.
• Employees: The vesting of restricted stock units is a positive for the employee, representing earned compensation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by an officer to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically reflect a change in the insider's outlook on the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider transaction, Stock sale, Restricted stock units, Tax withholding, Officer, Michael Charles Ferguson Hannay